IP Verse

Boult Wade Tennant Llp opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Boult Wade Tennant Llp

Patent Number:
EP4011915
Title:
Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Jul 10, 2024
Patent Number:
EP3548084
Title:
Methods For Determining Car-T Cells Dosing
Applicant:
JUNO THERAPEUTICS, INC.
Opposition Date:
May 21, 2024
Patent Number:
EP3384049
Title:
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-Vegf
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
May 1, 2024
Patent Number:
EP3363811
Title:
Method For Producing Fusion Protein Having Igg Fc Domain
Applicant:
ALTEOGEN INC.
Opposition Date:
Jan 18, 2024
Patent Number:
EP3984092
Title:
Organic Heat Transfer System, Method And Fluid
Applicant:
THE LUBRIZOL CORPORATION
Opposition Date:
Dec 28, 2023
Patent Number:
EP3302507
Title:
Diagnostic Methods For T Cell Therapy
Applicant:
KITE PHARMA, INC.
Opposition Date:
Nov 22, 2023
Patent Number:
EP2877854
Title:
Fusion Proteins And Methods Thereof
Applicant:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Opposition Date:
Jun 7, 2023
Patent Number:
EP3880802
Title:
Improved T Cell Manufacturing Process
Applicant:
CELGENE CORPORATION
Opposition Date:
Jun 7, 2023
Patent Number:
EP3752634
Title:
Dna Sequencing Using Hydrogel Beads
Applicant:
ILLUMINA, INC.
Opposition Date:
May 30, 2023
Patent Number:
EP3716992
Title:
Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
May 9, 2023

Competitors of Boult Wade Tennant Llp

DANA-FARBER CANCER INSTITUTE, INC.

REGENERON PHARMACEUTICALS, INC.

THE GENERAL HOSPITAL CORPORATION

Want to track Boult Wade Tennant Llp?

Feel free to send us a message here and we will get back to you